Bellevue Group AG
Bellevue Group AG reported 154 stocks worth $4.8B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are AMGN (7.5%), GILD (6.7%) and VRTX (6.3%). Compared with Q2 2026, the fund opened new positions in KOD, DMRA and ANRO, added to AMGN, REGN and INSM, trimmed GILD, ARGX and RVMD and sold out of RARE, CLDX and GLUE.
Latest filing: what Bellevue Group AG did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() AMGN Amgen Inc | $363M | 7.5% | 862K | +10K (+1%) | 8 of 8 | |
| 2 | ![]() GILD Gilead Sciences Inc | $321M | 6.7% | 2.2M | −8,080 (−0%) | 8 of 8 | |
| 3 | ![]() VRTX Vertex Pharmaceuticals I | $302M | 6.3% | 579K | No change | 8 of 8 | |
| 4 | ![]() ARGX Argenx SE | $279M | 5.8% | 291K | −10K (−3%) | 8 of 8 | |
| 5 | ![]() REGN Regeneron Pharmaceutical | $212M | 4.4% | 280K | +122K (+78%) | 8 of 8 | |
| 6 | ![]() RVMD Revolution Medicines Inc | $205M | 4.3% | 999K | −49K (−5%) | 8 of 8 | |
| 7 | ![]() INSM Insmed Inc | $172M | 3.6% | 1.5M | +115K (+8%) | 8 of 8 | |
| 8 | ![]() VRDN Viridian Therapeutics Inc | $146M | 3.0% | 7.1M | +377K (+6%) | 4 of 8 | |
| 9 | ![]() ORKA Oruka Therapeutics Inc | $137M | 2.8% | 1.6M | −16K (−1%) | 3 of 8 | |
| 10 | ![]() BIIB Biogen Inc | $135M | 2.8% | 598K | +598K (+176801%) | 8 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
NUVALENT INC | $130M | 1.1M |
CRINETICS PHARMACEUTICALS IN | $98M | 2.6M |
![]() RARE Ultragenyx Pharmaceutical in | $66.2M | 2M |
![]() CLDX Celldex Therapeutics Inc | $44.7M | 1.2M |
GALECTO INC | $42.1M | 1.6M |
🔒 Free account: see all 19.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Bellevue Group AG 13F FAQ
What does Bellevue Group AG own?
Bellevue Group AG reported 154 stocks worth $4.8B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are AMGN (7.5%), GILD (6.7%) and VRTX (6.3%). The table above lists every position in the filing (the top 10 without an account).
What did Bellevue Group AG buy and sell in Q3 2026?
Compared with Q2 2026: 25 new positions, 41 added to, 65 trimmed and 19 sold out. New positions include KOD, DMRA and ANRO. It sold all of RARE, CLDX and GLUE.
When will Bellevue Group AG file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Bellevue Group AG's portfolio worth?
The Q3 2026 filing reports $4.8B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.
























